RALINK TECHNOLOGY CORPORATION, A MEDIATEK COMPANY Cupertino, CA 2008 to 2010 Strategic Marketing/Business Development ManagerUBICOM Inc Sunnyvale, CA 2008 to 2008 Senior Product Marketing ManagerVENTURI WIRELESS Sunnyvale, CA 2006 to 2007 Director, Program Management, Product Management GroupPHILIPS ELECTRONICS NORTH AMERICA Briarcliff Manor, NY Dec 1998 to Sep 2006 Acting Product Manager / Senior Member of Technical Staff (2002 ~ 2006); Member of Technical Staff (1998 ~ 2002)
Education:
KELLOGG SCHOOL OF MANAGEMENT, NORTHWESTERN UNIVERSITY Chicago, IL 2006 Master of Business Administration in Management & StrategyRENSSELAER POLYTECHNIC INSTITUTE Troy, NY 1998 Master of Science in Electrical EngineeringTSINGHUA UNIVERSITY 1995 Bachelor of Science in Engineering Physics
Skills:
Strategic marketing, Strategic planning, business development, partnership development, product management
Vanderheyden Hall Inc Wynantskill, NY May 2008 to Sep 2009 Senior AccountantRotech Healthcare Inc Orlando, FL May 2007 to May 2008 Financial AnalystNYS of Taxation and Finance Albany, NY Aug 2006 to Dec 2006 INTERNSHIPPacific Antai Life Insurance Co. Ltd
Jul 2002 to May 2003 Accountant
Education:
University at Albany, State University of New York Albany, NY Dec 2006 Master of Science in Information ScienceUniversity at Albany, State University of New York Albany, NY May 2005 Master of Science in AccountingFudan University Jul 2002 Bachelor of Science in Accounting
Skills:
Proficient in ACL, MS Office (Word, Excel, PowerPoint, Access), FundEZ; Familiar with Windows, UNIX, SAS, SPSS, HTML, SQL, PHP, XML; Solid writing and oral communication skills in both English and Chinese
eriodically throughout Chinese history, rulers have sought to centralize control and isolate China from the outside. As Fei-Ling Wang of the Georgia Institute of Technology pointed out in The China Order: Centralia, World Empire, and the Nature of Chinese Power, such attempts result in disaster for China.
Date: Jul 15, 2022
Category: Business
Source: Google
Chinese COVID-19 Vaccine Phase 2 Trial Results: Safe and Induces an Immune Response
unogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial by Feng-Cai Zhu, Xu-Hua Guan, Yu-Hua Li, Jian-Ying Huang, Tao Jiang, Li-Hua Hou, Jing-Xin Li, Bei-Fang Yang, Ling Wang, We